Drugs / Lenzilumab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04314843 | May 2020 → Mar 2021 | aggressive B-cell non-Hodgkin lymphoma | Kite, A Gilead Company | Terminated | No outcome recorded |
| Phase 1 | NCT02546284 | Jul 2016 → Feb 2020 | chronic myelomonocytic leukemia | Humanigen, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04583969 | Oct 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01603277 | Jul 2012 → Jul 2013 | chronic asthma | Humanigen, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00995449 | Jan 2010 → Mar 2011 | rheumatoid arthritis | Humanigen, Inc. | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04534725 | Dec 2020 → Nov 2022 | COVID-19, cancer, viral respiratory tract infection | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 3 | NCT04351152 | May 2020 → Mar 2021 | COVID-19 | Humanigen, Inc. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-05-31 | Kite, A Gilead Company | Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma kitepharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lenzilumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02546284 ↗ |
| Known as | KB003 | “7 intravenous infusions of either 400 mg KB003 or placebo at baseline and weeks 2, 4, 8, 12, 16 and 20.” PMID 26739717 ↗ Jan 2016 |
| Action | Inhibit | “Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL3707325 ↗1“an anti-GM-CSF antibody (KB003)” PMID 26739717 ↗ Jan 2016 |
| Modality | Monoclonal antibody | “Anti-GM-CSF Monoclonal Antibody” NCT00995449 ↗ |
| Route | Intravenous | “KB003 IV x5 doses” NCT00995449 ↗ |
| Target | CSF2 | “Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL3707325 ↗ |